← Human Trials & Peer-Reviewed Studies
Concurrent Treatment with Vitamin K2 and D3 on Spine Fusion in Patients with Osteoporosis-Associated Lumbar Degenerative Disorders
Plain-language guide to PMID 34919073 (2022): controlled clinical trial study of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 34919073
- Journal
- Spine
- Year
- 2022
- Study type
- Controlled Clinical Trial
- Authors
- Zhang W et al. (9 authors)
- DOI
- 10.1097/BRS.0000000000004309
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this controlled clinical trial publication.
To address the early effects of concurrent treatment with vitamin K2 and vitamin D3 on fusion rates in patients who have undergone spinal surgery.
The Japanese Orthopedic Association Back Pain Evaluation Questionnaire (JOA-BPEQ) and visual analog scale (VAS) were used to assess the clinical and neurological symptoms.
Why It Was Studied
Intervertebral pseudarthrosis has been reported after transforaminal lumbar interbody fusion (TLIF) or posterior lumbar interbody fusion (PLIF), especially in patients with osteopenia or osteoporosis.
No study has assessed the early effects of concurrent treatment with vitamin K2 and vitamin D3 on fusion rates.
Who Took Part
Patients with osteopenia or osteoporosis who underwent TLIF or PLIF in their department were included.
Patients in the VK2+VD3 group received vitamin K2, vitamin D3, and calcium treatment, whereas subjects in the control group only received calcium and vitamin D3.
How the Study Was Run
A prospective and nonrandomized concurrent controlled trial.
Spine fusion was evaluated by computed tomography.
Bone mineral density (BMD) and bone metabolism markers were measured for osteoporotic evaluation.
What Was Measured
No study has assessed the early effects of concurrent treatment with vitamin K2 and vitamin D3 on fusion rates.
PubMed files the paper under topics including COVID-19, Collagen Type I, Intervertebral Disc Degeneration, Lumbar Vertebrae, Osteoporosis, Spinal Fusion and Vitamin K 2.
What This Means in Plain Language
This is a controlled clinical trial of Vitamin D, K2, Magnesium and Zinc.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2022 (Spine), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.